molnupiravir  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress molnupiravir
    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining <t>molnupiravir</t> (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).
    Molnupiravir, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/molnupiravir/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    molnupiravir - by Bioz Stars, 2022-07
    94/100 stars

    Images

    1) Product Images from "Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2-host protein-protein interaction network"

    Article Title: Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2-host protein-protein interaction network

    Journal: bioRxiv

    doi: 10.1101/2022.06.03.494640

    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining molnupiravir (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).
    Figure Legend Snippet: Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining molnupiravir (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).

    Techniques Used: Infection, Inhibition

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    MedChemExpress molnupiravir
    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining <t>molnupiravir</t> (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).
    Molnupiravir, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/molnupiravir/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    molnupiravir - by Bioz Stars, 2022-07
    94/100 stars
      Buy from Supplier

    Image Search Results


    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining molnupiravir (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).

    Journal: bioRxiv

    Article Title: Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2-host protein-protein interaction network

    doi: 10.1101/2022.06.03.494640

    Figure Lengend Snippet: Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining molnupiravir (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).

    Article Snippet: Compounds vorinostat (catalogue number S1047; Sellckchem), romidespin (catalogue number S3020; Sellckchem), spautin-1 (catalogue number S7888; Sellckchem), fedratinib (catalogue number S2736; Sellckchem), merimepodib (catalogue number S6689; Sellckchem), mycophenolic acid (catalogue number HYB0421; MedChem Express), (+)-JQ-1 (catalogue number HY13030; MedChem Express) and Molnupiravir (catalogue number HY125033 MedChem Express) were tested.

    Techniques: Infection, Inhibition

    EIDD-1931 inhibits SARS-CoV-2 replication in human lung epithelial Calu-3 cells. Cells were pretreated for 1 hour with differing EIDD-1931 concentrations, followed by infection with SARS-CoV-2 at a MOI of 0.01 for 1 hour. After 1 hour, media was replaced, and cells were cultured in the presence of drug for 24 hours at 37°C in a 5% CO2 incubator. ( A ) Virus yield in the cell supernatant was measured by quantitative RT-PCR of clarified culture supernatant by using primer and probe sets to quantify total viral RNA (N gene; genomic and subgenomic RNA). ( B ) IC 50 values were determined using results from the RT-PCR following log-based transformation of drug concentrations and normalization to percentage inhibition based on diluent alone controls by fitting to drug-dose response curves using Prism software. ( C ) Absence of toxicity ( > 90% viability; shown by dotted line) at highest EIDD-1931 concentration used for analysis of SARS-CoV-2 replication (40μM) was confirmed using CellTiter-Glo® 2.0 Assay (Promega, Corp., Madison, WI, USA) as per manufacturer’s protocol. For A to C, means are shown ± standard deviation.

    Journal: Research Square

    Article Title: Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

    doi: 10.21203/rs.3.rs-86289/v1

    Figure Lengend Snippet: EIDD-1931 inhibits SARS-CoV-2 replication in human lung epithelial Calu-3 cells. Cells were pretreated for 1 hour with differing EIDD-1931 concentrations, followed by infection with SARS-CoV-2 at a MOI of 0.01 for 1 hour. After 1 hour, media was replaced, and cells were cultured in the presence of drug for 24 hours at 37°C in a 5% CO2 incubator. ( A ) Virus yield in the cell supernatant was measured by quantitative RT-PCR of clarified culture supernatant by using primer and probe sets to quantify total viral RNA (N gene; genomic and subgenomic RNA). ( B ) IC 50 values were determined using results from the RT-PCR following log-based transformation of drug concentrations and normalization to percentage inhibition based on diluent alone controls by fitting to drug-dose response curves using Prism software. ( C ) Absence of toxicity ( > 90% viability; shown by dotted line) at highest EIDD-1931 concentration used for analysis of SARS-CoV-2 replication (40μM) was confirmed using CellTiter-Glo® 2.0 Assay (Promega, Corp., Madison, WI, USA) as per manufacturer’s protocol. For A to C, means are shown ± standard deviation.

    Article Snippet: Standard curves of MK-4482 and EIDD-1931 were made in lung homogenate from uninfected animals and subjected to irradiation to account for molecular degradation.

    Techniques: Infection, Cell Culture, Quantitative RT-PCR, Reverse Transcription Polymerase Chain Reaction, Transformation Assay, Inhibition, Software, Concentration Assay, Standard Deviation

    Morphometric analysis of viral antigen and drug concentration in the lungs. ( A ) A longitudinal cross section of the right lung was stained for viral antigen and scanned to measure the total amount of viral antigen present in the lung section. ( B ) EIDD-1931 concentrations in the lungs. ( A and B ) Blue circle, vehicle control; red square, pre-infection treatment; green triangle, post-infection treatment. Summary of results: ( A ) The area of lung staining positive for viral antigen showed a statistically significant difference between both of the MK-4482 treatment groups, compared to vehicle controls. No difference between individual treatment groups was present. For A and B, means are shown. ANOVA followed by Kruskal-Wallis analysis and a pairwise Wilcox test was used to analyze differences among groups. **p

    Journal: Research Square

    Article Title: Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

    doi: 10.21203/rs.3.rs-86289/v1

    Figure Lengend Snippet: Morphometric analysis of viral antigen and drug concentration in the lungs. ( A ) A longitudinal cross section of the right lung was stained for viral antigen and scanned to measure the total amount of viral antigen present in the lung section. ( B ) EIDD-1931 concentrations in the lungs. ( A and B ) Blue circle, vehicle control; red square, pre-infection treatment; green triangle, post-infection treatment. Summary of results: ( A ) The area of lung staining positive for viral antigen showed a statistically significant difference between both of the MK-4482 treatment groups, compared to vehicle controls. No difference between individual treatment groups was present. For A and B, means are shown. ANOVA followed by Kruskal-Wallis analysis and a pairwise Wilcox test was used to analyze differences among groups. **p

    Article Snippet: Standard curves of MK-4482 and EIDD-1931 were made in lung homogenate from uninfected animals and subjected to irradiation to account for molecular degradation.

    Techniques: Concentration Assay, Staining, Infection

    In vitro antiviral effect of EIDD-1931, favipiravir, suramin and ribavirin in Vero cells. ( A ) Dose–response effect of EIDD-1931, favipiravir, suramin and ribavirin on MAYV-induced CPE (MOI 0.01), quantified in Vero cells by the MTS/PMS method. Data shown are mean values ± standard deviations (SD) from three independent experiments. ( B – E ) The effect of different concentrations of ( B ) EIDD-1931, ( C ) favipiravir, ( D ) suramin and ( E ) ribavirin on the release of MAYV particles by infected Vero cells (MOI 0.01). Both viral RNA (genome copies/mL; blue) and infectious progeny virus (TCID 50 /mL; orange) were quantified at 48 h pi by real-time qRT-PCR and end-point titrations, respectively. Data shown are mean values ± SD from three independent experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p

    Journal: Microorganisms

    Article Title: Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

    doi: 10.3390/microorganisms9040734

    Figure Lengend Snippet: In vitro antiviral effect of EIDD-1931, favipiravir, suramin and ribavirin in Vero cells. ( A ) Dose–response effect of EIDD-1931, favipiravir, suramin and ribavirin on MAYV-induced CPE (MOI 0.01), quantified in Vero cells by the MTS/PMS method. Data shown are mean values ± standard deviations (SD) from three independent experiments. ( B – E ) The effect of different concentrations of ( B ) EIDD-1931, ( C ) favipiravir, ( D ) suramin and ( E ) ribavirin on the release of MAYV particles by infected Vero cells (MOI 0.01). Both viral RNA (genome copies/mL; blue) and infectious progeny virus (TCID 50 /mL; orange) were quantified at 48 h pi by real-time qRT-PCR and end-point titrations, respectively. Data shown are mean values ± SD from three independent experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p

    Article Snippet: Galidesivir, remdesivir and EIDD-1931 (β-D-N4-hydroxycytidine) were purchased from Medchem Express (Monmouth Junction, New Jersey, USA) and chloroquine from Sigma-Aldrich (Overijse, Belgium).

    Techniques: In Vitro, Infection, Quantitative RT-PCR

    Mechanism of action of EIDD-1931, favipiravir and suramin against MAYV. Delay of treatment effect of favipiravir (blue), suramin (orange) and EIDD-1931 (green) on ( A ) intracellular RNA and ( B ) infectious virus titers, determined at 10 h pi, using qRT-PCR and end-point titrations, respectively. Vero cells were infected with MAYV TC625 (MOI 1) and compounds were added 2 h prior to infection (−2), at the time of infection (0) or 2, 4, 6, 8 h pi. Data shown are mean values ± SD from three (favipiravir and suramin) or four (EIDD-1931) experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p

    Journal: Microorganisms

    Article Title: Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

    doi: 10.3390/microorganisms9040734

    Figure Lengend Snippet: Mechanism of action of EIDD-1931, favipiravir and suramin against MAYV. Delay of treatment effect of favipiravir (blue), suramin (orange) and EIDD-1931 (green) on ( A ) intracellular RNA and ( B ) infectious virus titers, determined at 10 h pi, using qRT-PCR and end-point titrations, respectively. Vero cells were infected with MAYV TC625 (MOI 1) and compounds were added 2 h prior to infection (−2), at the time of infection (0) or 2, 4, 6, 8 h pi. Data shown are mean values ± SD from three (favipiravir and suramin) or four (EIDD-1931) experiments. Significant differences from untreated virus control were analyzed by Kruskal–Wallis test (*, p

    Article Snippet: Galidesivir, remdesivir and EIDD-1931 (β-D-N4-hydroxycytidine) were purchased from Medchem Express (Monmouth Junction, New Jersey, USA) and chloroquine from Sigma-Aldrich (Overijse, Belgium).

    Techniques: Quantitative RT-PCR, Infection